Human Microbiome Market Growth Analysis 2018-2026 Including Global Top Players Merck & Co. Inc., Affymetrix Inc., Vithera Pharmaceuticals, Microbiome Therapeutics, LLC, Vedanta Biosciences, Inc., Metabiomics Corporation, Enterome Bioscience, Osel, Inc., Y

Microbial cells outnumber the human cells in the ratio 10:1 in a healthy human body. The human microbiome is the study of microbes present in the human body. These are beneficial microbes that carry out functions not performed by any gene in the human DNA and hence, they play a very important role in the human body. For example, these microbes produce certain vitamins that our body cannot make, break down our food, equip our immune system to recognize harmful foreign bodies, and produce anti-inflammatory compounds against it. The seemingly unending beneficial properties of the microbial population were unearthed in 2008, as part of the Human Microbiome Project (HMP) launched by the National Institutes of Health (NIH). The HMP project aims to characterize the human microbiome and analyze its role in human health and disease conditions.

The HMP has identified microbiome communities at several human body sites, including the gastrointestinal tract, skin, oral cavity, nasal passages, and urogenital tract. Currently, the HMP projects are focused on three areas – pregnancy and preterm birth, onset inflammatory bowel disease, and the onset of type 2 diabetes.

Download PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/182

Global Human Microbiome Market Taxonomy:

Research in this field has led to the emergence of various microbiome-based products. The global human microbiome market is analyzed on the basis of product type into probiotics, prebiotics, foods, medical foods, diagnostic devices, and other drugs and supplements. Prebiotics are increasing demand worldwide, with growing awareness about the various beneficial properties of the product such as improved digestion, better gut health, help with weight loss, and reduced risk of heart disease.

On the basis of application, the global human microbiome market is segmented into therapeutic and diagnostic. Therapeutic use of human microbiome is increasing with research yielding new applications and usage of the human microbiome. The market is thus expected to be inclining towards therapeutic applications in near future. Moreover, microbiome products are considered to be relatively safe, which creates a highly conducive environment for the growth of human microbiome industry.

The human microbiome can also be analyzed based on the technology used for conducting research in this field. These technologies include cell culture technology, high-throughput technology, omics technology, and computational tools. Products used for research include instruments (analyzers and other laboratory instruments) and consumables (kits and reagents).

Market participants can also understand the human microbiome market dynamics through analysis for different health conditions such as obesity, diabetes, acute diarrhea, mental disorders, autoimmune disorders, cancer, and other diseases.

Key Vendors of Human Microbiome Market:

Merck & Co. Inc., Affymetrix Inc., Vithera Pharmaceuticals, Microbiome Therapeutics, LLC, Vedanta Biosciences, Inc., Metabiomics Corporation, Enterome Bioscience, Osel, Inc., Yakult Honsha Co., Ltd., Second Genome, Inc., and E.I. Du Pont De Nemours and Company

Request for Customization of Research Report: https://www.coherentmarketinsights.com/insight/request-customization/182

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.